Apo2L/TRAIL and its death and decoy receptors

被引:726
|
作者
LeBlanc, HN [1 ]
Ashkenazi, A [1 ]
机构
[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA
来源
CELL DEATH AND DIFFERENTIATION | 2003年 / 10卷 / 01期
关键词
apoptosis; caspases; TNF superfamily; Bcl-2; bax;
D O I
10.1038/sj.cdd.4401187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apo2 ligand or tumour necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is one of the several members of the tumour necrosis factor (TNF) gene superfamily that induce apoptosis through engagement of death receptors (DRs). Apo2L/TRAIL interacts with an unusually complex receptor system of two DRs and three decoys. This protein has garnered intense interest as a potential candidate for cancer therapy because as a trimer it selectively induces apoptosis in many transformed cells but not in normal cells. While much of the early characterisation of Apo2L/TRAIL and its receptors relied on overexpression studies, recent work using untransfected cells has clarified how endogenous proteins transmit apoptotic signals from this ligand. In this review, we focus on the apoptotic signalling pathways stimulated by Apo2L/TRAIL and summarise what is known about its physiological role.
引用
收藏
页码:66 / 75
页数:10
相关论文
共 50 条
  • [21] New insights into apoptosis signaling by Apo2L/TRAIL
    Gonzalvez, F.
    Ashkenazi, A.
    ONCOGENE, 2010, 29 (34) : 4752 - 4765
  • [22] RNAi screen for novel regulators of Apo2L/TRAIL
    Punnoose, Elizabeth A.
    Lee, James
    Davis, David
    Amler, Lukas
    Ashkenazi, Avi
    Wagner, Klaus
    CANCER RESEARCH, 2006, 66 (08)
  • [23] New insights into apoptosis signaling by Apo2L/TRAIL
    F Gonzalvez
    A Ashkenazi
    Oncogene, 2010, 29 : 4752 - 4765
  • [24] Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
    Kamini Singh
    Arishya Sharma
    Maria C Mir
    Judith A Drazba
    Warren D Heston
    Cristina Magi-Galluzzi
    Donna Hansel
    Brian P Rubin
    Eric A Klein
    Alexandru Almasan
    Molecular Cancer, 13
  • [25] Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.
    Kischkel, FC
    Lawrence, DA
    Chuntharapai, A
    Schow, P
    Kim, KJ
    Ashkenazi, A
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (06) : 1171 - 1171
  • [26] TRAIL/APO2L expression in Barretts esophagus, dysplasia, and adenocarcinoma
    Popnikolov, NK
    Pasricha, PJ
    Norris, BA
    Adegboyega, PA
    Gatalica, Z
    LABORATORY INVESTIGATION, 2002, 82 (01) : 141A - 142A
  • [27] Human astrocytic brain tumors express APO2L/TRAIL
    Johannes Rieger
    Hiroko Ohgaki
    Paul Kleihues
    M. Weller
    Acta Neuropathologica, 1999, 97 : 1 - 4
  • [28] APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
    Anel, Alberto
    Martinez-Lostao, Luis
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2011, 5 (03) : 184 - 199
  • [29] Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
    David Lawrence
    Zahra Shahrokh
    Scot Marsters
    Kirsten Achilles
    Danny Shih
    Barbara Mounho
    Kenneth Hillan
    Klara Totpal
    Laura DeForge
    Peter Schow
    Jeffrey Hooley
    Steve Sherwood
    Roger Pai
    Susan Leung
    Lolo Khan
    Brian Gliniak
    Jeanine Bussiere
    Craig A. Smith
    Stephen S. Strom
    Sean Kelley
    Judith A. Fox
    Deborah Thomas
    Avi Ashkenazi
    Nature Medicine, 2001, 7 : 383 - 385
  • [30] Role of Apo2L/TRAIL in immunity: Applications to rheumatoid arthritis
    Luis Martinez-Lostao
    Alberto Anel
    World Journal of Rheumatology, 2012, (01) : 1 - 11